Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy

In ATTR-ACT, baseline or historical AF/AFL was prognostic for all-cause mortality in analyses with limited adjustment

jacc.org/doi/10.1016/j.…

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) is a rare, progressive, and often fatal genetic disease caused by mutations in the transthyretin (TTR) gene.

Read more 👉 lttr.ai/ASAeB

#AmyloidFibrils #Pharmacist #Healthcare #Quality #News

Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy | JACC: CardioOncology jacc.org/doi/10.1016/j.…

Pfizer's $PFE #Vyndaqel , for Transthyretin #Amyloidosis , surpassed Q1 sales at $1.1 billion. Despite patent expiry, Pfizer Inc. aims to extend exclusivity till 2028. Competitors await #FDA decisions. #BridgeBio and #Alnylam shares rise.
Stay informed: mellalta.com

We still don't know enough about the degree of silencing and clinical outcomes in transthyretin amyloidosis

This is from an Alnylam Pharmaceuticals presentation looking at modeling from APOLLO-A and mNIS+7

We will have HELIOS-B, CARDIO-TTRansform, and MAGNITUDE to help answer this question…

Q&A: An Update on Hereditary Transthyretin Amyloidosis medscape.com/viewarticle/q-…

Check out this insightful Q&A by Dr. Morie Gertz on the latest in hereditary transthyretin amyloidosis diagnosis and treatment. Stay updated on the advancements in this field. Read more here: wb.md/4bkFl1N

A new study has determined that patients with hereditary transthyretin-mediated amyloidosis (hATTR) due to a V1421 mutation have transthyretin amyloid polyneuropathy (ATTR-PN) more often than has been previously reported.

Read more: brnw.ch/21wJk9G

#RareDisease

Transthyretin Amyloidosis Market Size, Growth, Report 2030 marketresearchfuture.com/reports/transt…

#bangkokstyleonline #ข่าว VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure ift.tt/oy6iuet

More trials in #ATTR cardiomyopathy
MAGNITUDE is a 765 patient trial randomizing patients with ATTR CM to NTLA-2001 vs placebo

classic.clinicaltrials.gov/ct2/show/NCT06…

#CardioTwitter

Q&A: An Update on Hereditary Transthyretin Amyloidosis dlvr.it/T6Ngqz

Key Development: Intellia ($NTLA 🚀Stock Price: $23.6) Advances in PHASE3 Clinical Trial! New Frontiers in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Treatment.

Click for More: clinicaltrials.gov/study/NCT06128…
#StockMarket #economic #trading

#mobiledista #ข่าว VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure ift.tt/iOflvXF

💡 A unique case report detailing patisiran exposure during early pregnancy in a woman with hereditary transthyretin-related amyloidosis. Learn about the careful considerations and monitoring involved in managing this rare scenario.

Read more: journals.sagepub.com/doi/full/10.11…

Université de Lausanne

Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy - ScienceDirect.com dlvr.it/T6DVJM

A study has determined that computed tomography-based myocardial extracellular volume combined with additional indicators can reveal concealed transthyretin amyloid cardiomyopathy in patients with atrial fibrillation who are undergoing catheter ablation.

brnw.ch/21wJmul

Identification of new endocrine disruptive transthyretin ligands in polluted waters using pull-down assay coupled to non-target mass spectrometry
sciencedirect.com/science/articl…

Q&A: An Update on Hereditary Transthyretin Amyloidosis dlvr.it/T6QgpK